Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on May 31, 2019. The filing primarily addresses the appointment of a new Chief Executive Officer and President, as well as a change in the date of the 2019 Annual Meeting of Shareholders. The company is incorporated in California and its common stock is registered on the NYSE American.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- Executive Leadership Change: The Board of Directors appointed Ronald Andrews as President and Chief Executive Officer, effective July 1, 2019. The current CEO, William Annett, will remain in office until that date and is expected to transition into an advisory role.
- Board Committee Adjustments: Due to his new executive role, Mr. Andrews is stepping down from the Audit Committee and Compensation Committee of the Board of Directors.
- Annual Meeting Reschedule: The date for the 2019 Annual Meeting of Shareholders was moved from July 10, 2019, to July 17, 2019. The deadline for shareholder proposals and nominations (April 29, 2019) remains unchanged.
Guidance, Outlook, and Compensation Details
The filing contains no financial guidance or operational outlook. However, it details the compensatory arrangements for the new CEO, Ronald Andrews, under an Employment Agreement:
- Base Salary: $480,000 annually.
- Bonus: Eligible for annual bonuses based on predetermined company and individual objectives.
- Equity Awards:
- Initial Grant: Options to purchase 950,000 shares (25% vesting after one year; remainder vesting over 36 months).
- Second Grant: Options to purchase 50,000 shares vesting after one year of service.
- Restricted Stock Units (RSUs): 65,000 shares vesting after one year of service.
- Termination Provisions:
- Termination without "cause" or resignation for "good reason" triggers severance including 6 to 12 months of base salary (depending on tenure), COBRA health benefits for 12 months, and accelerated vesting of certain options.
- Change of Control within 12 months of termination results in full vesting of time-based options.
Investor Verification Checklist
- Verify the effective date of Ronald Andrews' appointment (July 1, 2019) and the transition plan for William Annett.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and performance metrics for bonuses.
- Confirm the new date for the 2019 Annual Meeting of Shareholders (July 17, 2019) to ensure proper voting participation.
- Check subsequent filings for the company's financial performance, as this 8-K contains no revenue or earnings data.